DIA Board of Directors Strengthening DIA’s Mission and Strategic Direction

DIA (founded as the Drug Information Association), a member-driven volunteer organization for global healthcare product development, recently announced the election of officers and directors to its Board of Directors. Members assume their respective positions July 1.  

The 2018-2019 DIA Board of Directors is as follows:

• Chair: Joseph Scheeren, PharmD, Senior Advisor R&D, Bayer AG
• Immediate Past Chair: John A. Roberts, MBA, CEO, Cancer Genetics, Inc.
• Chair-Elect: Rebecca Vermeulen, RPh, Head, Product Development Medical Affairs Customer Strategy, F.Hoffmann-La Roche Ltd.
• Secretary/Treasurer: Jeffrey S. Payne, CPA, CFO, Katabat

Directors:

*New board member

• Andrzej Czarnecki, MD, PhD, DSc, FFPM, Director, Deputy Qualified Person for Pharmacovigilance, Global Patient Safety, Eli Lilly and Company, Ltd.
• Angelika Joos, MPharm, Executive Director, Global Regulatory Policy, Merck Sharp & Dohme (Europe) Inc.
• Barbara Lopez Kunz, MS, Global Chief Executive, DIA
• Judith Ng-Cashin, MD, Chief Scientific Officer, Syneos Health
• Mike Rosenblatt, MD, Chief Medical Officer, Flagship Pioneering
• Jonathan Sheldon, PhD, SVP, Head, Bioinformatics Business Area, QIAGEN
• Lingshi Tan, PhD, Chairman and Chief Executive Officer, dMed Company Limited
• *Kihito Takahashi, MD, PhD, Vice President and Director, Development and Medical Affairs Division, GlaxoSmithKline K.K.
• *Cynthia Verst, PharmD, MS, President, Design and Delivery Innovation, IQVIA
• *Michael Romano, CPA, Partner, Finance and Accounting, Outsourcing, RSM US LLP

“Congratulations to Kihito Takahashi, Cynthia Verst, and Michael Romano for being elected by DIA members to the board as directors, and to Rebecca Vermeulen for being selected as Chair-Elect” said Barbara Lopez Kunz, Global Chief Executive, DIA. “I’m also thrilled to be working with Joseph Scheeren as the new Chair of the board as we continue to deliver our strategy that plays so well to DIA’s strengths and areas of distinction. As some of the brightest minds in their fields, these thought leaders will provide invaluable strategic insights and direction to DIA.

Their unique skills, experience, and dedication will undoubtedly guide us as we continue on our mission to accelerate the delivery of therapies to patients worldwide.”